II. History: Diabetes MellitusPharmacology
- 1922: Crude Insulin Extracts by Banting and Best
- 1940: NPH Insulin developed
- 1950: Sulfonylureas developed
- 1960: Biguanides off market
- 1970: Second Generation Sulfonylureas
III. Protocol: Blood Glucose Monitoring Goals
- Target Blood Glucose (>50% of readings in range)
- Children under age 6
- Before meals: 100-180 mg/dl
- Bedtime and overnight: 110-200 mg/dl
- Children age 6 to 12
- Before meals: 90-180 mg/dl
- Bedtime and overnight: 100-180 mg/dl
- Children age 13 to 19
- Before meals: 90-130 mg/dl
- Bedtime and overnight: 90-150 mg/dl
- Adult
- Fasting (before breakfast): <105 mg/dl
- Before Meals: 70-120 mg/dl
- Two hour post-prandial <160 mg/dl
- Before bedtime: 100-160 mg/dl
- Adjust target to Blood Glucose 100-160 mg/dl before meals IF
- Recurrent Hypoglycemia
- Decreased Life Expectancy
- Frail elderly
- Cognitive disorder
- Serious comorbid medical condition
- Children under age 6
- Target Hemoglobin A1C (check 3-4 times per year)
- Under age 6 years: 7.5 to 8.5%
- Age 6 to 12: <8.0%
- Age 13-19: <7.5%
- Age 20 and older (non-pregnant, esp. Type I Diabetes): <7.0%
- Preconception pregnancy (or low risk of Hypoglycemia): <6.5%
- Frail, elderly or severe Hypoglycemia risk or history: <8.0%
- Additional Monitoring
- Urine Ketone Indication (Type I Diabetes Mellitus)
- Blood Glucose exceeds 240 for 2 values
- Concurrent illness or infection
- Urine Ketone Indication (Type I Diabetes Mellitus)
IV. Protocol: Scheduled Blood Glucose Monitoring
- Individualized and negotiated
- Self-monitoring of Blood Glucose is associated with better glycemic control
- Minimum monitoring routine
- Type I Diabetes Mellitus
- Obtain Glucose at least three times daily
- Monitoring is often 6-10 per day or via continuous monitoring
- Type II Diabetes Mellitus
- At least once daily for those on Insulin, uncontrolled Diabetes Mellitus, or risk for Hypoglycemia
- At least 3-4 times weekly while titrating new medications
- Exception: Insulin (daily if titrating Basal insulin, 3x/day if titrating Bolus Insulin)
- Periodic monitoring is reasonable for well controlled Type II Diabetes Mellitus on Oral Hypoglycemics
- Type I Diabetes Mellitus
- Ideal monitoring routine
- Before meals (qAC)
- Before Exercise
- Bedtime (qHS)
- As needed for symptoms of Hypoglycemia
- Occassionally after meals (2 hours post-prandial)
- Monitoring in Special Circumstances
- See Diabetes Sick Day Management
- See Hypoglycemia Management
- Blood Sugar at 3 am
- Obtain prior to adjusting overnight Insulin
- Obtain if morning Hyperglycemia
- Hyperglycemia (Dawn Phenomena)
- Nocturnal Hypoglycemia (Somogyi Phenomena)
- Exercise in Diabetes Mellitus
- Consider 2 hour post-prandial Glucose (PPG) weekly
- PPG is earliest detectable glycemic abnormality
- PPG correlates best with Hemoglobin A1C
- PPG correlates with vascular complications
V. Protocol: Blood Glucose data utilization
- Imperative to review Blood Sugar logs frequently
- Certain monitors can download stored values to PC
- Correlate Blood Sugar readings with Hemoglobin A1C
- Review Blood Sugar trends between clinic visits
- If Hemoglobin A1C does not correlate with Glucose
- Check meter accuracy
- Assess patient finger stick Blood Sugar skills
- Monitor Blood Glucose more frequently
- Refer for diabetes education
- Adjust Management if
- Hypoglycemic Episodes (treat these first)
- Blood Glucose or Hemoglobin A1C target goals per age not met
- Example of adult indications for adjusted medications
- Fasting or pre-meal Serum Glucose exceeds 140 (>50% of readings)
- Bedtime Glucose exceeds 160 (>50% of readings)
- Hemoglobin A1C exceeds 7.0%
VI. Efficacy: Intensive Glucose lowering effects (on average goal of Hgb A1c <7.0%)
-
Type I Diabetes Mellitus: Significant benefit of intensive glycemic control
- DCCT results
- Cardiovascular disease risk reduced by 42% (and CV events by 57%)
- Retinopathy reduced by 63%
- Neuropathy reduced by 60%
- Nephropathy reduced by 54%
- Complication-free living increased by >15 years
- Life Expectancy extended by >5 years
- (1993) N Engl J Med 329:977-86 [PubMed]
- (1996) JAMA 276:1409-15 [PubMed]
- Nathan (2005) N Engl J Med 353(25): 2643-53 [PubMed]
- Significant reduction in cardiovascular events and mortality
- DCCT results
-
Type II Diabetes Mellitus: NO significant benefit of intensive glycemic control (although mixed early results)
- Increased mortality with intensive control (ACCORD)
- No significant benefit in cardiovascular disease or events (ACCORD)
- Minimal longterm cardiovascular benefit and no mortality benefit to intensive control
- Reduced nephropathy with intensive glycemic control (ADVANCE)
- Reduced microvascular complications (Retinopathy, nephropathy, Neuropathy) with intensive control (UKPDS)
- References